List of Bioverativ patents

Patents where

Current Assignee

Name

‌

Bioverativ

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10138291 Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof	Patent 10138291 was granted and assigned to Bioverativ on November, 2018 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	10138291	November 27, 2018
‌ US Patent 10287564 Procoagulant compounds	Patent 10287564 was granted and assigned to Bioverativ on May, 2019 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	10287564	May 14, 2019
‌ US Patent 11091534 Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof	Patent 11091534 was granted and assigned to Bioverativ on August, 2021 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11091534	August 17, 2021
‌ US Patent 11370827 Chimeric factor VIII polypeptides and uses thereof	Patent 11370827 was granted and assigned to Bioverativ on June, 2022 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11370827	June 28, 2022
‌ US Patent 9636416 Immunoglobulin chimeric monomer-dimer hybrids	Patent 9636416 was granted and assigned to Bioverativ on May, 2017 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	9636416	May 2, 2017
‌ US Patent 11382831 Device container	Patent 11382831 was granted and assigned to Bioverativ on July, 2022 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11382831	July 12, 2022
‌ US Patent 11192936 Factor VIII chimeric proteins and uses thereof	Patent 11192936 was granted and assigned to Bioverativ on December, 2021 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11192936	December 7, 2021
‌ US Patent 10058480 Device container	Patent 10058480 was granted and assigned to Bioverativ on August, 2018 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	10058480	August 28, 2018
‌ US Patent 11372008 Blood factor monitoring assay and uses thereof		‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11372008	June 28, 2022
‌ US Patent 10548953 Factor VIII-XTEN fusions and uses thereof	Patent 10548953 was granted and assigned to Bioverativ on February, 2020 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	10548953	February 4, 2020
‌ US Patent 11401322 Immunoglobulin chimeric monomer-dimer hybrids		‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11401322	August 2, 2022
‌ US Patent 10421798 Factor VIII compositions and methods of making and using same	Patent 10421798 was granted and assigned to Bioverativ on September, 2019 by the United States Patent and Trademark Office.		‌ Bioverativ	United States Patent and Trademark Office	10421798	September 24, 2019
‌ US Patent 10457745 Anti-complement C1s antibodies	Patent 10457745 was granted and assigned to Bioverativ on October, 2019 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	10457745	October 29, 2019
‌ US Patent 10947269 Purification of chimeric FVIII molecules	Patent 10947269 was granted and assigned to Bioverativ on March, 2021 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	10947269	March 16, 2021
‌ US Patent 10010622 Factor VIII chimeric and hybrid polypeptides, and methods of use thereof	Patent 10010622 was granted and assigned to Bioverativ on July, 2018 by the United States Patent and Trademark Office.		‌ Bioverativ	United States Patent and Trademark Office	10010622	July 3, 2018
‌ US Patent 11578098 On-column viral inactivation methods	Patent 11578098 was granted and assigned to Bioverativ on February, 2023 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11578098	February 14, 2023
‌ US Patent 11192944 Methods of inducing complement activity	Patent 11192944 was granted and assigned to Bioverativ on December, 2021 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11192944	December 7, 2021
‌ US Patent 11266720 Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof	Patent 11266720 was granted and assigned to Bioverativ on March, 2022 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11266720	March 8, 2022
‌ US Patent 10881742 Factor VIII chimeric and hybrid polypeptides, and methods of use thereof	Patent 10881742 was granted and assigned to Bioverativ on January, 2021 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	10881742	January 5, 2021
‌ US Patent 10588949 Factor IX polypeptide formulations	Patent 10588949 was granted and assigned to Bioverativ on March, 2020 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	10588949	March 17, 2020
‌ US Patent 11642398 Factor IX polypeptide formulations	Patent 11642398 was granted and assigned to Bioverativ on May, 2023 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11642398	May 9, 2023
‌ US Patent 10898554 Factor IX polypeptides and methods of use thereof	Patent 10898554 was granted and assigned to Bioverativ on January, 2021 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	10898554	January 26, 2021
‌ US Patent 11008561 Optimized factor IX gene	Patent 11008561 was granted and assigned to Bioverativ on May, 2021 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11008561	May 18, 2021
‌ US Patent 11168125 Immunoglobulin chimeric monomer-dimer hybrids	Patent 11168125 was granted and assigned to Bioverativ on November, 2021 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11168125	November 9, 2021
‌ US Patent 11246926 Polynucleotides encoding anti-C1s antibodies	Patent 11246926 was granted and assigned to Bioverativ on February, 2022 by the United States Patent and Trademark Office.	‌ Bioverativ	‌ Bioverativ	United States Patent and Trademark Office	11246926	February 15, 2022

Results per page:

63 results

0 selected

63 results

0 selected